EGFR and non-small cell lung carcinoma: In the Chinese Phase III trial FURLONG [4], compared with gefitinib, the third‐generation EGFR‐TKI furmonertinib in the first‐line treatment of NSCLC with sensitive EGFR mutations can significantly prolong the median progression‐free survival (PFS) (19.3 months vs. 9.9 months, HR = 0.46) and central nervous system PFS (20.8 months vs. 9.8 months, HR = 0.40).